Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CERT
Certara, Inc.
|
$104.6M | $0.11 | 3.04% | 150.07% | $12.54 |
|
DOCS
Doximity, Inc.
|
$157.6M | $0.38 | 7.73% | 20.37% | $67.90 |
|
DRIO
DarioHealth Corp.
|
$5.7M | -$2.42 | -32.08% | -68.96% | $18.25 |
|
GDRX
GoodRx Holdings, Inc.
|
$194.5M | $0.09 | -2.9% | 420.34% | $4.88 |
|
NRC
National Research Corp.
|
-- | -- | -- | -- | -- |
|
SPOK
Spok Holdings, Inc.
|
$35.9M | $0.24 | 2.09% | 18.18% | $20.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CERT
Certara, Inc.
|
$8.91 | $12.54 | $1.4B | 131.93x | $0.00 | 0% | 3.45x |
|
DOCS
Doximity, Inc.
|
$43.78 | $67.90 | $8.2B | 34.92x | $0.00 | 0% | 14.22x |
|
DRIO
DarioHealth Corp.
|
$10.04 | $18.25 | $24.1M | -- | $0.00 | 0% | 5.57x |
|
GDRX
GoodRx Holdings, Inc.
|
$2.77 | $4.88 | $940.2M | 32.25x | $0.00 | 0% | 1.27x |
|
NRC
National Research Corp.
|
$18.81 | -- | $426.2M | 26.69x | $0.12 | 2.55% | 3.08x |
|
SPOK
Spok Holdings, Inc.
|
$12.93 | $20.00 | $266.3M | 16.16x | $0.31 | 9.67% | 1.92x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CERT
Certara, Inc.
|
22.36% | 0.910 | 15.74% | 1.94x |
|
DOCS
Doximity, Inc.
|
1.02% | 1.251 | 0.08% | 7.23x |
|
DRIO
DarioHealth Corp.
|
29.69% | 1.040 | 75.99% | 3.72x |
|
GDRX
GoodRx Holdings, Inc.
|
47.58% | 0.637 | 37.77% | 2.62x |
|
NRC
National Research Corp.
|
84.83% | 2.343 | 28.57% | 0.39x |
|
SPOK
Spok Holdings, Inc.
|
4.71% | 0.927 | 2.07% | 0.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CERT
Certara, Inc.
|
$50.9M | $6.8M | 0.79% | 1.02% | 6.53% | $25.5M |
|
DOCS
Doximity, Inc.
|
$152.1M | $67.9M | 24.06% | 24.35% | 40.28% | $91.6M |
|
DRIO
DarioHealth Corp.
|
$3M | -$9.5M | -28.66% | -41.55% | -189.42% | -$7.4M |
|
GDRX
GoodRx Holdings, Inc.
|
$161.2M | $26.4M | 2.63% | 4.78% | 13.48% | $58M |
|
NRC
National Research Corp.
|
$20M | $7.7M | 17.01% | 61.55% | 22.36% | $10.2M |
|
SPOK
Spok Holdings, Inc.
|
$20M | $4.5M | 10.33% | 10.88% | 13.38% | $7.6M |
Doximity, Inc. has a net margin of 1.46% compared to Certara, Inc.'s net margin of 36.83%. Certara, Inc.'s return on equity of 1.02% beat Doximity, Inc.'s return on equity of 24.35%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
CERT
Certara, Inc.
|
48.67% | $0.01 | $1.4B |
|
DOCS
Doximity, Inc.
|
90.25% | $0.31 | $1.1B |
Certara, Inc. has a consensus price target of $12.54, signalling upside risk potential of 39.82%. On the other hand Doximity, Inc. has an analysts' consensus of $67.90 which suggests that it could grow by 55.09%. Given that Doximity, Inc. has higher upside potential than Certara, Inc., analysts believe Doximity, Inc. is more attractive than Certara, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
CERT
Certara, Inc.
|
6 | 7 | 0 |
|
DOCS
Doximity, Inc.
|
8 | 6 | 1 |
Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Doximity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Doximity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Certara, Inc. pays -- of its earnings as a dividend. Doximity, Inc. pays out -- of its earnings as a dividend.
Certara, Inc. quarterly revenues are $104.6M, which are smaller than Doximity, Inc. quarterly revenues of $168.5M. Certara, Inc.'s net income of $1.5M is lower than Doximity, Inc.'s net income of $62.1M. Notably, Certara, Inc.'s price-to-earnings ratio is 131.93x while Doximity, Inc.'s PE ratio is 34.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.45x versus 14.22x for Doximity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
CERT
Certara, Inc.
|
3.45x | 131.93x | $104.6M | $1.5M |
|
DOCS
Doximity, Inc.
|
14.22x | 34.92x | $168.5M | $62.1M |
DarioHealth Corp. has a net margin of 1.46% compared to Certara, Inc.'s net margin of -41.48%. Certara, Inc.'s return on equity of 1.02% beat DarioHealth Corp.'s return on equity of -41.55%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
CERT
Certara, Inc.
|
48.67% | $0.01 | $1.4B |
|
DRIO
DarioHealth Corp.
|
60.22% | -$3.05 | $106.6M |
Certara, Inc. has a consensus price target of $12.54, signalling upside risk potential of 39.82%. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 81.77%. Given that DarioHealth Corp. has higher upside potential than Certara, Inc., analysts believe DarioHealth Corp. is more attractive than Certara, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
CERT
Certara, Inc.
|
6 | 7 | 0 |
|
DRIO
DarioHealth Corp.
|
3 | 1 | 0 |
Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.
Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Certara, Inc. pays -- of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend.
Certara, Inc. quarterly revenues are $104.6M, which are larger than DarioHealth Corp. quarterly revenues of $5M. Certara, Inc.'s net income of $1.5M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, Certara, Inc.'s price-to-earnings ratio is 131.93x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.45x versus 5.57x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
CERT
Certara, Inc.
|
3.45x | 131.93x | $104.6M | $1.5M |
|
DRIO
DarioHealth Corp.
|
5.57x | -- | $5M | -$2.1M |
GoodRx Holdings, Inc. has a net margin of 1.46% compared to Certara, Inc.'s net margin of 0.57%. Certara, Inc.'s return on equity of 1.02% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
CERT
Certara, Inc.
|
48.67% | $0.01 | $1.4B |
|
GDRX
GoodRx Holdings, Inc.
|
82.22% | $0.00 | $1.1B |
Certara, Inc. has a consensus price target of $12.54, signalling upside risk potential of 39.82%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $4.88 which suggests that it could grow by 76.29%. Given that GoodRx Holdings, Inc. has higher upside potential than Certara, Inc., analysts believe GoodRx Holdings, Inc. is more attractive than Certara, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
CERT
Certara, Inc.
|
6 | 7 | 0 |
|
GDRX
GoodRx Holdings, Inc.
|
6 | 5 | 0 |
Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.
Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Certara, Inc. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.
Certara, Inc. quarterly revenues are $104.6M, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. Certara, Inc.'s net income of $1.5M is higher than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Certara, Inc.'s price-to-earnings ratio is 131.93x while GoodRx Holdings, Inc.'s PE ratio is 32.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.45x versus 1.27x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
CERT
Certara, Inc.
|
3.45x | 131.93x | $104.6M | $1.5M |
|
GDRX
GoodRx Holdings, Inc.
|
1.27x | 32.25x | $196M | $1.1M |
National Research Corp. has a net margin of 1.46% compared to Certara, Inc.'s net margin of 11.54%. Certara, Inc.'s return on equity of 1.02% beat National Research Corp.'s return on equity of 61.55%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
CERT
Certara, Inc.
|
48.67% | $0.01 | $1.4B |
|
NRC
National Research Corp.
|
57.82% | $0.18 | $94.4M |
Certara, Inc. has a consensus price target of $12.54, signalling upside risk potential of 39.82%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Certara, Inc. has higher upside potential than National Research Corp., analysts believe Certara, Inc. is more attractive than National Research Corp..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
CERT
Certara, Inc.
|
6 | 7 | 0 |
|
NRC
National Research Corp.
|
0 | 0 | 0 |
Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.
Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.55% to investors and pays a quarterly dividend of $0.12 per share. Certara, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Certara, Inc. quarterly revenues are $104.6M, which are larger than National Research Corp. quarterly revenues of $34.6M. Certara, Inc.'s net income of $1.5M is lower than National Research Corp.'s net income of $4M. Notably, Certara, Inc.'s price-to-earnings ratio is 131.93x while National Research Corp.'s PE ratio is 26.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.45x versus 3.08x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
CERT
Certara, Inc.
|
3.45x | 131.93x | $104.6M | $1.5M |
|
NRC
National Research Corp.
|
3.08x | 26.69x | $34.6M | $4M |
Spok Holdings, Inc. has a net margin of 1.46% compared to Certara, Inc.'s net margin of 9.46%. Certara, Inc.'s return on equity of 1.02% beat Spok Holdings, Inc.'s return on equity of 10.88%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
CERT
Certara, Inc.
|
48.67% | $0.01 | $1.4B |
|
SPOK
Spok Holdings, Inc.
|
58.95% | $0.15 | $156.1M |
Certara, Inc. has a consensus price target of $12.54, signalling upside risk potential of 39.82%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 62.41%. Given that Spok Holdings, Inc. has higher upside potential than Certara, Inc., analysts believe Spok Holdings, Inc. is more attractive than Certara, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
CERT
Certara, Inc.
|
6 | 7 | 0 |
|
SPOK
Spok Holdings, Inc.
|
1 | 0 | 0 |
Certara, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.
Certara, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.67% to investors and pays a quarterly dividend of $0.31 per share. Certara, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.
Certara, Inc. quarterly revenues are $104.6M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. Certara, Inc.'s net income of $1.5M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, Certara, Inc.'s price-to-earnings ratio is 131.93x while Spok Holdings, Inc.'s PE ratio is 16.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Certara, Inc. is 3.45x versus 1.92x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
CERT
Certara, Inc.
|
3.45x | 131.93x | $104.6M | $1.5M |
|
SPOK
Spok Holdings, Inc.
|
1.92x | 16.16x | $33.9M | $3.2M |
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.